Published in Cancer Res on December 01, 1969
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J Exp Med (1980) 1.72
Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med (1976) 1.69
Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60
The age related responses of New Zealand mice to a murine sarcoma virus. Clin Exp Immunol (1971) 1.11
Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep (2012) 0.97
Immunopathology of New Zealand Black mice treated with antilymphocyte globulin. Immunology (1971) 0.84
Harnessing the Microbiome to Enhance Cancer Immunotherapy. J Immunol Res (2015) 0.79
Immunity to murine sarcoma virus induced tumours. 3. Analysis of the cell populations involved in protection from lethal tumour progression of sublethally irradiated, MSV inoculated, mice. Br J Cancer (1974) 0.79
Effect of pretreatment with immune serum on murine sarcoma virus (Moloney) tumour induction and growth. Br J Cancer (1977) 0.78
Immunity to tumours of the murine leukaemia-sarcoma virus complex. Br J Cancer Suppl (1973) 0.77
Effects of time of initial exposure to MSV sarcoma on bone induction by dentine matrix implants and on orthotopic femora. Int J Mol Sci (2010) 0.75
The effect of cyclophosphamide on MSV-H oncogenesis. Br J Cancer (1977) 0.75
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Bone-marrow transplantation (first of two parts). N Engl J Med (1975) 3.33
Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med (1981) 2.50
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36
Peroxidase-H2O2-halide system: Cytotoxic effect on mammalian tumor cells. Blood (1975) 2.25
Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol (1980) 2.20
Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. J Immunol (1975) 2.06
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood (1985) 1.81
Allogeneic marrow grafting for treatment of aplastic anemia. Blood (1974) 1.76
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med (1982) 1.76
Hickman catheter infections in patients with malignancies. Medicine (Baltimore) (1984) 1.61
Induction and regression of primary moloney sarcoma virus-induced tumors in mice. Cancer Res (1967) 1.60
Antigenicity of a virus-induced murine sarcoma (Moloney). Cancer Res (1967) 1.58
Immunologic, virologic, and pathologic studies of regression of autochthonous Moloney sarcoma virus-induced tumors in mice. Cancer Res (1968) 1.57
Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol (1996) 1.50
Interstitial pneumonia and cytomegalovirus infection as complications of human marrow transplantation. Transplantation (1973) 1.48
Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med (1979) 1.44
Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med (1986) 1.41
Very low dose alpha-2b interferon for the treatment of hairy cell leukemia. Blood (1989) 1.41
Aplastic anaemia treated by marrow transplantation. Lancet (1972) 1.39
Cross-resistance to the transplantation of syngeneic Friend, Moloney, and Rauscher virus-induced tumors. Cancer Res (1968) 1.39
Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol (1996) 1.34
Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2. J Immunol (1981) 1.27
Efficacy of cryopreserved spleen cells in murine tumor immunotherapy. Transplantation (1972) 1.27
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med (1984) 1.24
Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol (1983) 1.23
Comparative studies on the induction of transplantation resistance in BALB-c and C57BL-6 mice in three murine leukemia systems. Cancer Res (1967) 1.22
Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med (1984) 1.22
Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med (1974) 1.22
Leukaemic transformation of engrafted human marrow cells in vivo. Lancet (1972) 1.17
Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood (1976) 1.11
H-2 restriction of adoptive immunotherapy of advanced tumors. J Immunol (1981) 1.10
Marrow transplantation in thirty "untransfused" patients with severe aplastic anemia. Ann Intern Med (1980) 1.09
Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. Cancer Res (1980) 1.08
Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood (1979) 1.08
Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood (1974) 1.06
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood (2000) 1.06
Opportunistic infection and interstitial pneumonia following marrow transplantation for aplastic anemia and hematologic malignancy. Transplant Proc (1976) 1.05
Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol (1976) 1.05
Bone marrow transplantation in patients aged 45 years and older. Blood (1986) 1.04
Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet (1982) 1.03
Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation. J Clin Oncol (1988) 1.02
Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res (1987) 1.02
Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am (1997) 1.00
Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation. Int J Radiat Oncol Biol Phys (1982) 1.00
Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med (1989) 1.00
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Semin Oncol (1997) 0.98
Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. Transplantation (1982) 0.98
Allogeneic marrow grafting for hematologic malignancy using HL-A matched donor-recipient sibling pairs. Blood (1971) 0.98
One-hundred-ten patients with aplastic anemia (AA) treated by marrow transplantation in Seattle. Transplant Proc (1978) 0.97
An immunochemotherapeutic system for the treatment of a transplanted Moloney virus-induced lymphoma in mice. Cancer Res (1969) 0.96
Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J Immunol (1977) 0.96
Allogeneic marrow grafting for treatment of aplastic anemia: a follow-up on long-term survivors. Blood (1976) 0.95
Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol (1987) 0.94
Current status of bone marrow transplantation for aplastic anemia and acute leukemia. Blood (1977) 0.93
Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood (1991) 0.93
Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med (1979) 0.92
Chemotherapy of established graft-versus-host disease in mice. Transplantation (1972) 0.92
Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res (1989) 0.92
Studies of immunological reactivity following syngeneic or allogeneic marrow grafts in man. Transplantation (1973) 0.92
Treatment of aplastic anemia by bone marrow transplantation in identical twins. Blood (1980) 0.92
Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2. Cancer J Sci Am (1997) 0.91
Models for syngeneic adoptive chemoimmunotherapy of murine leukemias. Ann N Y Acad Sci (1976) 0.91
Studies on the neutralization of the oncogenicity of Friend, Moloney, and Rauscher viruses. Cancer Res (1968) 0.91
Changing trends in marrow transplantation for aplastic anemia. Bone Marrow Transplant (1992) 0.91
Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst (1986) 0.89
Secondary malignancies after marrow transplantation. Exp Hematol (1984) 0.89
Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. Transplantation (1982) 0.88
Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood (1996) 0.88
Paroxysmal nocturanal hemoglobinuria and marrow failure treated by infusion of marrow from an identical twin. Ann Intern Med (1976) 0.88
The pathogenesis of aplastic anemia. Semin Hematol (1981) 0.88
Cyclophosphamide-induced chimerism. Cancer Res (1968) 0.87
High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer (1981) 0.87
Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential. Recent Results Cancer Res (1982) 0.87
Treatment of preleukemic syndromes with marrow transplantation. Blood (1987) 0.87
Treatment of chronic granulocytic leukemia with chemoradiotherapy and transplantation of marrow from identical twins. N Engl J Med (1982) 0.87
High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol (1996) 0.86
Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Med (1984) 0.86
Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. Cancer Res (1989) 0.86
Long-term survival after marrow transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia. Ann Intern Med (1984) 0.85
Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant (1996) 0.85
Adoptive chemoimmunotherapy of cancer in animals: a review of results, principles, and problems. Ann N Y Acad Sci (1976) 0.85
Allogeneic and syngeneic marrow transplantation following high dose dimethylbusulfan, cyclophosphamide and total body irradiation. Bone Marrow Transplant (1987) 0.85
Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation (1986) 0.84
Immunobiological studies of tumors induced by murine sarcoma virus (Kirsten). Cancer Res (1972) 0.84
Studies on the growth and regression of a transplantable Moloney sarcoma. Cancer Res (1967) 0.84
A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod (1988) 0.84
Effect of cortisone on oncogenesis by murine sarcoma virus (Moloney). Cancer Res (1968) 0.84
Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant (1991) 0.84
Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol (1986) 0.84
Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant (1996) 0.83
Paroxysmal nocturnal haemoglobinuria and refractory marrow failure treated by marrow transplantation. Br J Haematol (1973) 0.83
Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma. Cancer Chemother Rep (1975) 0.83
Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease. J Clin Oncol (1987) 0.83
Correlation of the relative response index with marrow graft rejection in patients with aplastic anemia. Transplantation (1976) 0.83